Barinthus Biotherapeutics (NASDAQ:BRNS) just reported results for the fourth quarter of 2023.
- Barinthus Biotherapeutics reported earnings per share of -45 cents. This was above the analyst estimate for EPS of -50 cents.
- The company did not report any revenue for the quarter.